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SIGNIFICANCE
People with chronic skin conditions often experience im-
pairments in their quality of life. Several questionnaires 
exist for measuring quality of life in skin disease, e.g. the 
Dermatology Life Quality Index (DLQI) and Skindex-29. In 
this study we asked 28 patients with eczema or psoriasis 
to what degree these two measures capture what matters 
to them. Overall, the patients felt that Skindex-29 better 
captured their lived experience due to its items on emo-
tions, a longer recall period of 4 weeks and greater ease of 
understanding. However, both DLQI and Skindex-29 lack 
important content such as impact of disease on professio-
nal relationships.
Little is known about which quality of life measure best 
captures the lived experience of people with a chronic 
skin condition. The purpose of this study was to ex-
plore patients’ views on the Dermatology Life Quality 
Index (DLQI) and Skindex-29. Participants were 
adults (n = 28) with a diagnosis of eczema or psoria-
sis who completed the DLQI and the Skindex-29 be-
fore being interviewed about the content and format 
of these questionnaires. Interviews were analysed 
using content analysis. Participants were generally sa-
tisfied with length and layout of both questionnaires. 
However, the majority preferred the Skindex-29 for its 
ease of understanding, use of a longer recall period 
and incorporation of items on a variety of emotions. 
Participants reported both questionnaires failing to in-
corporate important aspects of their lives, for instance 
impact on professional relationships. Participants voi-
ced limitations in both measures but overall felt Skin-
dex-29 better captured their lived experience. 
Key words: quality of life; DLQI; Skindex-29; qualitative study; 
content validity; lived experience.
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In any one-year, more than half of UK’s population (54%) experience a skin disorder (1). Skin conditions 
can have a profound impact on a persons’ quality of life 
(QoL), affecting physical, emotional, psychological and 
social aspects. A recent systematic review reported that 
health-related QoL (HRQoL) in people with psoriasis is 
significantly compromised, especially in young adults 
and in women (2). Other studies have documented the 
impact of psoriasis on profession (career choices and 
decisions), family (relationship, time, intimacy etc.), 
sexual life, and education (3, 4). Studies on eczema 
have highlighted that disease control “goes beyond the 
skin” affecting psychological and social aspects, and 
impacting on everyday activities (5). A high burden of 
psychiatric disorders, including depression, anxiety and 
suicidal ideation (6, 7), has been reported in studies of 
patients with eczema and acne suggesting that the op-
timal management of chronic skin conditions requires 
a holistic approach, encompassing management of the 
skin lesions alongside the psychological sequelae and 
impact on HRQoL. 
HRQoL is a key outcome in health research including 
clinical trials. The multidimensional construct captures 
information on patient’s physical and mental health status 
and the impact of health status on quality of life (8). It 
is important to examine the construct of HRQoL as it 
focuses on the well-being of a person, which is mostly 
affected by the healthcare provided, changes in health 
status, and the available social support (9).
Dermatology specific HRQoL questionnaires are 
commonly used when assessing disease burden and 
evaluating new treatments. The 2017 NICE guideline on 
psoriasis recommends that the severity of the disease is 
assessed regularly using HRQoL questionnaires (10). The 
British Association of Dermatologists (BAD) outlines the 
approaches necessary for achieving ‘high-quality care 
(11), stressing the value of ‘patient experience’ in addi-
tion to safe and effective care. The European Academy of 
Dermatology and Venereology (EADV) also highlights 
the importance of QoL measurement in dermatology 
clinical practice, emphasizing various benefits of routine 
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use of HRQoL measures in routine practice (12). Two 
frequently used measures are the Dermatological Life 
Quality Index (DLQI) (13) and the Skindex-29 (14), 
with others, such as the Dermatology Quality of Life 
Scales (15), the Dermatology-specific Quality of Life 
instrument (16), used less often. The use of qualitative 
methods in the development of both the DLQI and the 
Skindex was limited. In the development of the DLQI, 
120 patients from an outpatient dermatology department 
were asked to write down all the different ways their skin 
disease affected them, from which 49 different aspects 
were identified and ranked according to frequency (17). 
The development of the Skindex was based on published 
literature and ‘directed focus sessions’ with patients, 
physicians and nurses without further details being re-
ported (18). Further, it it is unclear which instrument best 
captures the recent/current impact of skin disease on the 
individual when compared to each other.
Therefore the purpose of this study was to explore 
patients’ views of format and content of the DLQI and 
Skindex-29 using a qualitative research approach. 
MATERIAL AND METHODS
Study design and sampling strategy
This was a qualitative study using face to face, semi-structured, 
in-depth interviews in adults (>18) with a physician diagnosis 
of eczema or psoriasis. We excluded those not fluent in English, 
or unable to give informed consent or with concomitant chronic 
disease (with the exception of asthma, so as not to exclude those 
with eczema). 
Recruitment 
Convenience sampling was undertaken by distributing leaflets 
about the study in the outpatient departments of our local hospitals 
and public spaces (such as libraries and coffee shops) in Brighton 
and Hove. A telephone number was written on the leaflets and 
advertisements so that patients could directly contact the research 
team to discuss eligibility and other questions before arranging a 
time and place for the interview. Once the potential participants 
were identified, eligibility criteria were checked and selection of 
participants was done either by direct approach from the researcher 
or by nurses and dermatologists.
Data collection and analysis
Participants began by completing the two questionnaires: 
– DLQI, a 10-item validated questionnaire available in > 90 langu-
ages, which since its introduction in 1994 has been used in > 40 
different skin conditions (13, 17). DLQI assesses the impact of 
the patient’s skin on symptoms, feelings, daily activities, leisure, 
work or study, close relationships and treatment during the 
previous week. Items are presented as questions with response 
options of ‘not at all’, ‘a little’, ‘a lot’ and ‘very much’. Eight 
questions also have a ‘not relevant’ response option. 
– Skindex-29 is also a validated instrument (14). It has 3 scales 
addressing emotions (10 items), symptoms (7 items) and functio-
ning (12 items). Each item is presented as a statement, with the 
response options of ‘never’, ‘rarely’, ‘sometimes’, ‘often’, and 
‘all the time’. Questions relate to the preceding 4-week period.
The face to face semi-structured interview which followed 
completion of the questionnaires encouraged participants through 
open questions, to critically evaluate the structure and content of 
these two questionnaires. The interviewers encouraged participants 
to talk freely about aspects of their skin disease that were bother-
some to them, including how their skin affected their QoL, and 
whether the questionnaire items captured this. As an aide, a topic 
guide (Table I) was referred to during interviews to ensure that 
the interview did not deviate too much between researchers. The 
topic guide was formulated based on a similar study in patients 
with asthma (19) and modified through a mock interview and 
discussions within the research team. 
The two interviewers (PP and SS) had no involvement in the 
clinical care of participants. The interviewers were trained to 
maintain neutrality and use open questions, encouraging new 
ideas and thoughts to emerge. Interviews were recorded using a 
digital voice recorder and were transcribed manually. Data were 
analysed in a step-by-step process using thematic content analysis 
as suggested by Burnard (20). The process involves a step-by-step 
process of open coding and categorisation – a structured method 
which is useful in organizing complex textual data in a systematic 
and transparent manner. 
Two researchers analysed the first 14 transcripts separately 
before meeting to discuss and finalise the codes to be used. The 
coding process was iterative; the identified themes from the two 
researchers were discussed with the wider research team and an 
agreement was reached for the main themes. 
Ethics and clinical governance approval were obtained from 
the NRES Committee South West Exeter and Research & Deve-
lopment Office, Royal Sussex County Hospital (11/SW/0333). 
RESULTS
Twenty-eight participants (17 male) with a mean age of 
48 years (range 18–77) took part in the study. Eleven 
participants had eczema (mean duration 30 years) and 
17 had psoriasis (mean duration 18 years). Two patients 
were identified through local libraries, the remainder 
were attendees at Dermatology out-patient clinics. In-
terviews lasted between 15-40 min.
Questionnaire structure
Participants were generally satisfied with the length and 
the overall layout of both questionnaires and found them 
easy to complete: “It [Skindex -29] was very simply laid 
out; very easy to understand. And you could zip through it 
quite quickly.” (P2). 
Table I. Topic guide used for interview process
Ø Introduction
Ø Overall impression of each questionnaire
Ø Format of questionnaires
   Layout 
   Length
   Format of the questions
   Response options
Ø Individual questions 
   Phrasing 
   Comprehensibility
   Content
Ø Whether questions reflect patient’s day-to-day experience of living with their 
skin condition (relevant content)
Ø Impacts of having a skin condition not addressed by the questionnaires 
(missing content)
Ø Preference for either questionnaire
Ø Any further recommended changes or improvement
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“... very structured [DLQI] – and the way it is numbered 
… easy to go through I think.” (P7).
In terms of the format, the statements in the Skindex-29 
were considered to be “quicker to read and get the answer 
in your head” (P7) as they were structured in first person. 
In contrast, the question format of DLQI was perceived 
as “someone else is asking the questions” even though par-
ticipants were self-completing the questionnaire (P24), 
making it harder to think and contemplate the answers. 
One patient wanted more space between the questions 
and suggested using arrows instead of dots for clarity 
(Skindex-29). Others commented that the ‘Not relevant’ 
option in the DLQI appears detached and needs to be 
better integrated with the text.
Questionnaire content
The majority of participants affirmed that both ques-
tionnaires broadly captured their QoL: “I think there’s 
a good range of questions, some of which in 50 odd years 
I have not been asked. So, I’m pleased to see those kinds 
of things there. Just about the effect that it has not only on 
work, but on your social life, interpersonal life and on your 
intimate life.” (P19)
When comparing the two questionnaires, most parti-
cipants favoured the Skindex-29. They described it as 
“comprehensive” and “relate personally” (P8), covering 
a wide spectrum of issues ranging from social, psycho-
logical, physical and sexual. In contrast, the DLQI was 
described as more “generic” (P25), failing to address 
the emotional impacts of skin disease. Some participants 
commented that the two questionnaires were comple-
mentary; Skindex-29 better capturing emotions whereas 
the DLQI captured impact the disease on activities: “…
Skindex-29 is more about how do you ‘feel’ about it… You’re 
depressed, you’re angry, seems to be a more emotional 
approach to the problem. And [DLQI] is actually saying 
on a day-to-day basis, over the last week, has it interfered 
with your shopping or looking after your home or garden. 
So DLQI seems to be ‘action’, and Skindex-29 seems to be 
‘emotion’” (P18).
Recall period
The Skindex-29’s 4-week recall period was preferred to 
the one-week of the DLQI; many participants commen-
ted that a month would include at least one outbreak or 
flare-up, when their skin condition impacted maximally.
“... I mean psoriasis, as I understand it, is a cyclical 
condition. So it goes up and down, and up and down. If you 
asked me that questionnaire – the one-week questionnaire 
[DLQI]– about last week, you might catch me at a point 
where it has gone right down and the lesions aren’t parti-
cularly painful or itchy, whereas the four week one [Skin-
dex-29] would catch, probably, most of the cycle.” (P13)
Some participants recommended that the questionnaire 
focus should be about exacerbations or times of maximal 
impact. One respondent was concerned Skindex-29’s 
4-week recall period might capture coping strategy rather 
than the actual impact of the symptoms.
 “I think that that questionnaire [Skindex-29] captures 
a state of mind over four weeks as opposed to this [DLQI] 
that captures maybe the physical negativities of psoriasis 
over the last week. I felt that was more sort of mental – how 
are you coping with the psoriasis as opposed to what the 
actual physical discomfort” (P9).
Another participant favoured one week recall period of 
DLQI stating that it might capture the true reflection of 
the condition “a really accurate snapshot of the last seven 
days, I think that you can answer this with less thinking and 
possibly with slightly more accuracy” (P9).
Ambiguous and repetitive phrases 
The lack of clarity regarding the various phrases used 
in the Skindex-29 questionnaire was a recurrent theme. 
Patients mentioned that phrases used were ‘difficult’ 
and ambiguous. Questions had “a kind of similar sort of 
angle” creating a sense of repetitiveness of items.
“I find Question 3 [in Skindex-29] quite difficult, “I worry 
that my skin condition may be serious” -Well, if that’s im-
plying that I think it might be ‘cancer’, then no. But does it 
cause me serious ‘problems’ over my life? Then yes... so I 
don’t quite know how to answer that question. So, it might 
need to be a bit more specific, for me, it would be. Because 
what do you mean by ‘serious’? Seriously inhibiting my life 
OR maybe serious as in a disease?” (P18).
It was suggested that phrases with similar meaning 
could be grouped together to allow participants to se-
lect the more relevant one, “I would sort of group those 
[indicating ashamed, embarrassed, and frustrated] so that 
people can make a comparison and give you a more ac-
curate answer”. (P9). The issue of repetition of similar 
phrases was further highlighted by another patient: “I 
thought that I had started the same one again, because I 
thought somewhere in here it says ‘Am I ashamed?’ ‘Am I 
embarrassed?’ I think there is a similarity in that question 
to be honest. I think you could have one question which 
said ‘are you ashamed or embarrassed’ (or ashamed/em-
barrassed)” (P18).
But other participants welcomed this granulation as 
it enabled them to capture the variety in their emotions: 
“Very thorough, in terms of, you’ve alternated the words 
(Skindex-29), one minute --- I am irritated, the next minute 
- my skin makes me angry, my skin is sensitive…So you 
can take on board the different kind of embarrassments, 
humiliation…. I do feel sometimes, that humiliation and 
embarrassment are different” (P18). 
Missing items
Participants identified areas missing from each of the 
questionnaires. Area of perceived neglect in Skindex-29 
related to items regarding treatment and referral process, 
and how the treatment adherence interferes with daily 
routine were missing from the Skindex-29 questionnaire: 
“The only thing that isn’t captured there …is understanding 
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and dealing with the process of treatment.” (P13). “Just 
about how the treatment interferes with your routine, and 
how it affects your skin as well” (P24). 
Whilst both questionnaires have a question relating to 
work, participant felt that the impact of their skin con-
ditions on employment options is not clearly captured 
by either questionnaire. Some explained how their skin 
condition limited their careers: “The quality of jobs I did 
was actually lower than my qualifications. I have worked 
part-time instead of full-time due to the eczema interfering 
on a daily basis” (P18). Others discussed the disease 
impact on professional relationships: “I work for lots of 
people from different companies and I do notice some people 
seem – ‘Ooh, I don’t really want to shake that hand’. Or 
they will shake my hand with a flat hand” (P9).
Participants commented that their perceptions and 
experiences were fluid, and responses were influenced 
by past experience, the duration of their skin condition 
and season of the year: “Because how you approach it 
and how you experienced it before, makes you answer this 
question differently… For instance, I could say my skin isn’t 
very irritating, but I could say actually I have forgotten 
that it was irritating last night. But because it wasn’t as 
irritating as it was 10 years ago, how do I actually answer 
that?” (P18).
Some said they had lived with a skin problem for so 
long that they had no choice but to cope. This transition 
from feelings of helplessness to reluctant acceptance was 
not covered in the questionnaires: “... I think you would 
find that more older people would go ... ‘it is boring and it 
is tedious but I can live with it’…And more younger people 
would go ‘it is hell and I want to commit suicide’.” (P4).
In recognition of these absolute and relative shifts in 
their quality of life there were requests for questionnaires 
be administered regularly in routine clinical practice: 
“...it strikes me that, in terms of an initial assessment, or 
even an assessment for someone returning to the clinic…
you know it’s quite possible that (pause) you don’t just run 
the survey once, you know, you might run it every little 
while…” (P19).
Sensitive and irrelevant question items 
Participants reported not all items asked in DLQI 
and Skindex-29 were relevant to them, often cited 
were sexual relationships and certain activities (e.g. 
gardening, sports): “Does it affect you when you are 
gardening?’(DLQI) and things like that. I don’t know how 
many people are doing gardening around here.” (P1).
When their disease excluded them from these activities 
they were not always certain how to respond, as ticking 
the ‘never’ response in Skindex-29 erroneously implied 
that their disease was without impact. Although ‘Not Re-
levant’ response option is stated in the DLQI, this option 
was not available in the Skindex-29: “‘My skin condition 
interferes with my sex life’ – well, that’s irrelevant. I think 
there should be a ‘not-relevant’ box [in Skindex-29].” (P20).
DISCUSSION
Participants were generally satisfied with the length and 
layout of the two frequently used dermatology-specific 
QoL questionnaires (DLQI and Skindex-29), but found 
some items were ambiguous, repetitive or irrelevant. The 
majority preferred the Skindex-29 as it was perceived to 
be easier to understand, used a longer recall period and 
better captured a variety of emotions and experiences. 
The DLQI, on the other hand, was perceived to overlook 
the emotional aspect experienced by people with skin 
disease. The topics not adequately covered by either 
questionnaire were coping strategies, treatment and side 
effects, previous experience with the disease, impact due 
to seasonal variation and limitation in job choices. 
Participants in our study were more critical of the DLQI 
than the Skindex-29. DLQI’s failure to address emotional 
impact were also highlighted in a previous systematic 
review (21[AQ1]). The review concluded that the DLQI 
fails to adequately capture the emotional and mental 
aspects of the patient’s QoL. Indeed, the DLQI does not 
capture relevant items such as sleep and swimming but 
includes questions regarding relationships with friends 
and relatives which might have little relevance to patients 
with mild to moderate atopic dermatitis (23). Also, the 
‘not relevant’ response option in DLQI has been suggested 
to raise a concern in content validity of the measure. A 
study using data from two surveys in patients with pso-
riasis found that close to 40% of patients provided at least 
one ‘not relevant’ response, particularly women, elderly 
patients and those with low educational background (24).
The quest for authenticity regarding instrument de-
velopment has been highlighted recently, emphasizing 
the importance of robust development and content 
validation of dermatology specific patient reported out-
comes (PROs) (25). Patient involvement is generally 
encouraged when developed PRO tools, but in reality, 
patients are not always involved and when they are 
their level of involvement varies considerably (26). The 
design and development of QoL measurements is time 
consuming and complex; striving to achieve a balance 
between robust psychometrics and patient preferences 
may not always be achievable. Additionally, patient 
suggestions may not always relate to QoL. For example, 
participants in this study often wished to know exactly 
what triggered or exacerbated their skin condition and 
were disappointed by the lack of information provided 
by their healthcare provider. Also, patients mentioned 
that items regarding treatment and its side-effect were 
missing from the questionnaire. Although this uncertainty 
about the pathogenesis of skin conditions and the lack 
of information highlights a need for further research, 
understanding of these matters falls outside the remit of a 
QoL of questionnaire. Similarly, including questions that 
relate to seasonal variation, an external factor, may also 
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be considered outside the realm of QoL. Similarly, for 
limitation of job choice, one could argue that while this 
is important when considering life as a whole, it does not 
fit within a questionnaire with a recall period of several 
weeks or a month. This suggests that the content validity 
of the questionnaire should have a balance between the 
lay and the professional perspective (27). 
The findings of our study corroborate with the previous 
research that has looked at QoL questionnaires in a simi-
lar fashion. A study exploring patients’ views of 3 com-
monly used asthma specific QoL questionnaires reported 
that patients’ perception varied across the questionnaires; 
one questionnaire was perceived to focus on ‘emotions’ 
one ‘medical’ and the other ‘non-medical’ (28). Another 
study, eliciting patients’ opinion on content and format 
of 3 asthma-specific questionnaires, also reported similar 
findings (29). A recent study describing the process on 
new questionnaire construction in severe asthma has 
highlighted the need when developing questionnaires that 
are fit for purpose to engage patients as partners from the 
beginning, not merely as sources of information (30).
The missing contents highlighted by the participants 
in our study have also been emphasized in previous 
qualitative studies among patients with skin disease.  A 
recently published study of patients with psoriasis repor-
ted that patients find it difficult to adhere to treatment 
as they interfere with the physical and psychological 
demands of everyday living (31).  Seasonal variations 
in disease symptoms, and adjustment and coping me-
chanism adapted by patients have also been discussed 
previously (3, 5, 31). The issues regarding the impact of 
skin disease on career prospects have been documented, 
with patients reporting limited employment options due 
to their physical appearance or time consuming treatment 
schedule (4, 31).  
Our study is the first exploration of the patients’ per-
spectives in relation to existing skin-specific QoL ques-
tionnaires but it has some limitations (participants were 
all Caucasian with either eczema or psoriasis). Further 
studies are needed that include other ethnic groups and 
other dermatological conditions. We recognise that ex-
cluding participants with concomitant chronic diseases 
might have resulted in less reflective real life experience. 
However, as our aim was to specifically understand 
whether dermatology specific QoL questionnaires cap-
ture the lived experience of people living with a skin 
condition, involving patients with other chronic condi-
tions may have resulted in a less clear understanding of 
the impact of the respective skin disease on everyday 
life. Using convenience sampling rather than purposive 
sampling may be considered another limitation of our 
study, but necessary because of time and money cons-
traints. Information on the perceived severity of partici-
pants’ skin condition would have been of value to further 
characterize the sample and to demonstrate diversity and 
should be included in further studies.   
In conclusion, from the patients’ perspective the 
Skindex-29 seems to be preferable for assessing QoL in 
inflammatory skin disease due to its ability to capture a 
variety of emotions and experiences and use of a longer 
recall period. However, views were diverse and some par-
ticipants commented how the Skindex-29 and the DLQI 
complemented each other. Further research is needed to 
elicit participants’ views in a more diverse sample, varied 
settings and considering further available questionnaires.
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